Intravitreal triamcinolone acetonide for cystoid macular edema in nonischemic central retinal vein occlusion
Intravitreal triamcinolone acetonide for cystoid macular edema in nonischemic central retinal vein occlusion
复制标题
DOI：
10.1016/j.ajo.2005.01.001
复制
发表时间：
2005-05-01
影响因子：
4.2
通讯作者：
O'Donnell, A
中科院分区：
文献类型：
--
作者：
Williamson, TH;O'Donnell, A
目得：目的探讨玻璃体腔注射曲安奈德治疗视网膜中央静脉阻塞（CRVO）所致黄斑囊样水肿的疗效。0设计：非比较性、前瞻性、干预性病例系列：方法：在临床实践中，18例非缺血性CRVO和黄斑囊样水肿患者入组。两毫克的曲安奈德被注射到每个病人的一只眼睛的玻璃体中。结果测量光学相干断层扫描和视力的平均中央视网膜厚度为1，mm。结果：术前症状的平均持续时间为2个月（SD，1.3个月）。10名患者需要重复注射复发性囊样黄斑水肿（平均1.8次注射）。平均视力从20/300显著改善至1个月时的20/166（P = .007）、2个月时的20/100（P = .0005）、3个月时的20/130（P = .007）和6个月时的20/150（P = .02），但在12个月时再次恶化至20/270（不显著）。视网膜厚度有显著改善，从518 μ m到1个月时的363 μ m（P = 0.03），2个月时的304 μ m（P = 0.04），3个月时的353 μ m（P = 0.01），但从6个月（平均值383 μ m）和12个月（平均值406 μ m）的表现没有改善。11例患者出现眼内压升高，需要干预。玻璃体内曲安奈德没有防止侧支循环的形成，这是在10 patients.CONCLUSION：玻璃体内皮质类固醇注射是非常有效的逆转囊样黄斑水肿，提高视力在最近，发病非缺血性CRVO在第6个月，但不幸的是，这是不能持续1年。(c)2005年，Elsevier Inc. All rights reserved.
PURPOSE: The effectiveness of intravitreal triamcinolone acetonide in the treatment of cystoid macular edema from central retinal vein occlusion (CRVO) was investigated. 0DESIGN: A noncomparative, prospective, interventional case series.METHODS: In a clinical practice, 18 patients were enrolled with nonischemic CRVO and cystoid macular edema. Two milligrams of triamcinolone acetonide were injected into the vitreous of only one eye from each patient. The outcome measures were 1,mm mean central retinal thickness on optical coherence tomography and visual acuity.RESULTS: Mean duration of symptoms before surgery was 2 months (SD, 1.3 months). Ten patients required repeated injections for recurrent cystoid macular edema (mean, 1.8 injections). Mean visual acuity significantly improved from 20/300 to 20/166 (P = .007) at 1 month, 20/100 (P = .0005) at 2 months, 20/130 (P = .007) at 3 months, and 20/150 (P = .02) at 6 months but deteriorated again to 20/270 (not significant) at 12 months. There was a significant improvement in retinal thickness from presentation 518 mu m, to 363 mu m (P = .03) at 1 month, 304 mu m (P = .04) at 2 months, and 353 mu m (P = .01) at 3 months but not from presentation at 6 months (mean, 383 mu m) and 12 months (mean, 406 mu m). Eleven patients suffered intraocular pressure rises requiring intervention. Intravitreal triamcinolone acetonide did not prevent collateral circulation formation, which was seen in 10 patients.CONCLUSION: Intravitreal corticosteroid injection is very effective in reversing cystoid macular edema and improving visual acuity in recent,onset nonischemic CRVO in the first 6 months, but this is unfortunately not sustained at 1 year. (c) 2005 by Elsevier Inc. All rights reserved.